Last reviewed · How we verify
NCT07242963
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
trial in Medulloblastoma Recurrent in 300 participants. Currently enrolling.
30 December 2035
Quick facts
| Lead sponsor | Mohammad H. Abu Arja |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 30 September 2025 |
| Primary completion | 30 December 2035 |
| Estimated completion | 30 December 2035 |
| Sites | 2 locations across United States |
Conditions studied
- Medulloblastoma Recurrent — all drugs for Medulloblastoma Recurrent →
- Medulloblastoma, Childhood, Recurrent — all drugs for Medulloblastoma, Childhood, Recurrent →
- Medulloblastoma, SHH-activated and TP53 Mutant — all drugs for Medulloblastoma, SHH-activated and TP53 Mutant →
- Medulloblastoma, SHH-activated and TP53 Wildtype — all drugs for Medulloblastoma, SHH-activated and TP53 Wildtype →
Sponsor
Mohammad H. Abu Arja
Who can join
Adults 3 to 50, any sex, with Medulloblastoma Recurrent or Medulloblastoma, Childhood, Recurrent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to create a biobank for patients diagnosed with Sonic Hedgehog Medulloblastoma at Baylor College of Medicine/Texas Children's Cancer Center. A biobank is a facility that stores and manages biological samples (such as blood, tissue, or DNA) from individuals, along with detailed health information, for use in medical research to study diseases and develop new treatments. The investigators are requesting participants' permission to add their information and samples to this biobank. Being in this research study is voluntary; it is the participant's choice. If the participant joins this study, they can still stop at any time. If the participant decides to participate, the investigators will review the participant's clinical medical records, demographics, treatment history, family history, and imaging. The investigators will also collect biological samples from the participant and the biological parents' buccal swabs (optional). The participation in this biobank will last about 5 years from the decision to participate. Why am I being asked to participate? The participant or their child is invited to participate in this study if the participant or their tumor may have a U1 mutation. U1 mutation is associated with an error in the gene that splices the tumor DNA, leading to random splicing that may increase the tumor mutation burden and generate novel tumor neoantigens (targets). Studying the U1 mutation will enable the investigator to design more effective therapies and guide future treatments for patients with relapsed or refractory sonic hedgehog medulloblastoma, thereby improving their outcomes and quality of life. Moreover, the investigators aim to determine whether germline mutations inherited from parents may increase the risk of medulloblastoma in their offspring. The participant will receive no direct benefit from their participation in this study. However, participation in this study may help the investigators better understand SHH Medulloblastomas and benefit other patients in the future.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07242963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Medulloblastoma Recurrent
Currently open trials in the same condition.
- NCT05057702 — Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma · NA · recruiting
- NCT03911388 — HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07242963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mohammad H. Abu Arja
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07242963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing